Jasper Therapeutics, INC Form 4 insider transactions

Jeet Mahal, COO of Jasper Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Ron Martell, CEO of Jasper Therapeutics, received stock options and performance-based restricted stock units, as detailed in a recent SEC filing.

Edwin Tucker, Chief Medical Officer of Jasper Therapeutics, acquired 400 shares of voting common stock through the company's 2021 Employee Stock Purchase Plan on June 7, 2024.

Anna French, a director at Jasper Therapeutics, was granted stock options to purchase 7,500 shares of voting common stock on June 6, 2024.

Christian Nolet, a director of Jasper Therapeutics, acquired 7,500 stock options on June 6, 2024, at an exercise price of $25.41.

Judith Shizuru, a director at Jasper Therapeutics, was granted stock options to purchase 7,500 shares of voting common stock at an exercise price of $25.41, exercisable starting June 6, 2025.

Vishal Kapoor, a director at Jasper Therapeutics, granted power of attorney and acquired 7,500 stock options on June 6, 2024.

Director Thomas G. Wiggans acquired 7,500 stock options in Jasper Therapeutics, Inc. on June 6, 2024.

Scott Brun, a director at Jasper Therapeutics, granted power of attorney to Ronald Martell and Herb Cross and acquired 7,500 stock options.

Kurt von Emster, a director at Jasper Therapeutics, was granted stock options for 7,500 shares on June 6, 2024, according to a recent SEC filing.

Jeetinder Singh Mahal, COO of Jasper Therapeutics, exercised stock options and sold 900 shares of voting common stock at an average price of $26.4358, pursuant to a pre-arranged 10b5-1 trading plan.